Drug Search Results
More Filters [+]

Vorasidenib

Alternative Names: vorasidenib, ag-881, ag881, ag 881
Latest Update: 2024-06-27
Latest Update Note: Clinical Trial Update

Product Description

Vorasidenib, an investigational, oral, selective, brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, is currently being evaluated in the registration-enabling Phase 3 INDIGO study as a potential treatment for patients with residual or recurrent Grade 2 non-enhancing glioma. (Sourced from: https://investor.agios.com/news-releases/news-release-details/agios-presents-updated-data-phase-1-dose-escalation-study)

Mechanisms of Action: IDH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Agios
Company Location: CAMBRIDGE MA 02139
Company CEO: Jacqualyn A. Fouse
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vorasidenib

Countries in Clinic: Canada, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Glioma

Phase 1: Astrocytoma|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

INDIGO

P3

Active, not recruiting

Glioma

2028-10-27

jRCT2061220059

P3

Recruiting

Glioma

2028-03-31

ViCToRy

P1

Not yet recruiting

Glioma

2025-08-01

CL1-95032-005

P1

Recruiting

Astrocytoma

2025-03-31

Recent News Events